Vanda Pharma Stock Price, News & Analysis

Vanda Pharmaceuticals Inc. (VNDA) announced Q2 2022 revenues of $64.4 million, a 5% decline from Q2 2021. Net product sales for HETLIOZ® were $41.2 million (-7%), and Fanapt® sales were $23.2 million (-1%). The company reported a net income of $2.6 million, down from $9.7 million in Q2 2021. For the year-to-date, total revenues of $124.6 million also reflect a 5% decrease. Vanda expects total revenues for 2022 to range from $240 million to $280 million.

Vanda Pharmaceuticals (Nasdaq: VNDA) plans to release its second quarter 2022 financial results on August 3, 2022, after market close. A conference call to discuss the results will be held at 4:30 PM ET on the same day. Investors can access the call via phone or through Vanda's website, where a replay will be available from 8:30 PM ET on August 3 until 8:30 PM ET on August 10. Vanda focuses on developing therapies to meet significant medical needs.

Vanda Pharmaceuticals (VNDA) announced its participation in the Jefferies 2022 Global Healthcare Conference set for June 9, 2022, at 3:30 p.m. ET in New York City. The corporate presentation will be available live on Vanda's website. Investors are encouraged to join early to ensure proper access. An archived version of the conference will be accessible on the website for approximately 30 days post-event. Vanda focuses on developing innovative therapies to meet significant medical needs and improve patient lives.

Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in the SLEEP 2022 conference in Charlotte, North Carolina, from June 4-8, 2022. On June 7, scientific presentations will focus on topics such as genetic aberrations linked to sleep disturbances and observational studies on sleep-wake phase disorders. Key presentations by Dr. Sandra Paulina Smieszek will include a novel missense variant in Melanopsin associated with delayed sleep. Vanda aims to develop innovative therapies for unmet medical needs.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation at Digestive Disease Week (DDW) 2022, taking place from May 21-24 in San Diego, CA. The company will present two significant studies by Dr. Sandra Paulina Smieszek, Head of Genetics. The first presentation on May 21 focuses on macrophage polarization in gastroparesis, while the second on May 23 discusses the gene set enrichment analysis in Ehlers Danlos syndrome patients with gastroparesis. For more details, visit DDW's website.

Vanda Pharmaceuticals (Nasdaq: VNDA) reported a net loss of $6.4 million for Q1 2022, a significant shift from a net income of $8.7 million in Q1 2021. Total net product sales decreased by 4% to $60.2 million, with HETLIOZ® sales down 6% to $37.0 million. The company is optimistic about expanding access to HETLIOZ® for Medicaid patients and completing the Fanapt® bipolar study by year-end. Financial guidance for 2022 is set at $240 to $280 million in total revenues, with a year-end cash expectation exceeding $440 million.

Vanda Pharmaceuticals (VNDA) will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT (7:00 p.m. ET) in Las Vegas, Nevada. The presentation will be available live on the company's website, and an archived version will be accessible for approximately 30 days following the event. Vanda focuses on developing innovative therapies to meet high unmet medical needs for patients.

Vanda Pharmaceuticals (Nasdaq: VNDA) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call is scheduled for 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can participate via phone or by accessing a live broadcast on Vanda's website. A replay will be available starting at 7:30 PM ET the same day until May 12, 2022. Vanda is focused on developing innovative therapies for unmet medical needs.

Vanda Pharmaceuticals (VNDA) reported Q4 and full-year 2021 results, showcasing total net product sales of $68.0 million in Q4 and $268.7 million for the year, reflecting increases of 1% and 8%, respectively. HETLIOZ® sales were $44.1 million in Q4, while Fanapt® reached $24.0 million. Net income for Q4 decreased to $7.1 million from $8.2 million in Q4 2020, but annual net income rose to $33.2 million from $23.3 million. Vanda anticipates 2022 revenue guidance of $240 to $280 million. A Phase III study of tradipitant did not meet its primary endpoint, prompting further analysis.